Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients

Journal of Periodontology

Volumn 67, Issue 6, 1996, Pages 597-602

  Ball, D E ^a   McLaughlin, W S ^b   Seymour, R A ^b   Kamali, F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Department of Restorative Dentistry ^*

Author keywords

5 (4 hydroxyphenyl) 5 phenylhydantoin adverse effects; epilepsy complications; gingival hyperplasia etiology; phenytoin adverse effects

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; DRUG METABOLITE; PHENYTOIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; EPILEPSY; FEMALE; GINGIVA HYPERPLASIA; GINGIVA HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PREVALENCE;

EID: 0030014837     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.1996.67.6.597     Document Type: Article

References (40)

1. Kimball OP. The treatment of epilepsy with sodium diphenyl hydantoinate. JAMA 1939;112:1244-1245.
2. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. J Oral Surg 1972;34:898-906.
3. Chang T, Glazko AJ. Phenytoin. Biotransformation. In: Woodbury DM, Penry JK, Pippenger CE, eds. Antiepileptic Drugs, 2nd ed. New York: Raven Press; 1982;209-226.
4. Maynert EW. The metabolic fate of diphenylhydantoin in the dog, rat and man. J Pharmacol Exp Ther 1960;130:275-284.
5. Hassell TM, Page RC. The major metabolite of phenytoin (Dilantin) induces gingival overgrowth in cats. J Periodont Res 1978;13:280-282.
6. Hassell TM. Epilepsy and the oral manifestations of phenytoin therapy. In: Myers HM, ed. Monographs in Oral Science, Vol. 9. Basel: Karger; 1981;116-202.
7. Babcock JR, Nelson GH. Gingival hyperplasia and Dilantin content of saliva: a pilot study. J Am Dent Assoc 1964;68:195-198.
8. Conard GJ, Jeffay H, Boshes L, Steinberg AD. Levels of 5,5-diphenylhydantoin and its major metabolite in human serum, saliva and hyperplastic gingiva. J Dent Res 1974;53:1323-1329.
9. Girgis SS, Staple PH, Miller WA, Sedransk N, Thompson T. Dental root abnormalities and gingival overgrowth in epileptic patients receiving anticonvulsant therapy. J Periodontol 1980;51:474-482.
10. Hassell T, O'Donnell J, Pearlman J, Tesini D, Murphy T, Best H. Phenytoin-induced gingival overgrowth in institutionalised epileptics. J Clin Periodontol 1983;11:242-253.
11. Dahllof G, Modeer T. The effect of a plaque control program on the development of phenytoin-induced gingival overgrowth. A 2-year longitudinal study. J Clin Periodontol 1986;13:845-849.
12. Modeer T, Dahllof G. Development of phenytoin-induced gingival overgrowth in non-institutionalised epileptic children subjected to different plaque control programs. Acta Odontol Scand 1987;45:81-85.
13. Silness J, Loë H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
14. Saxer UP, Mühlemann HR. Motivation and aufklarung. Schweiz Meschr Zahnheilk 1975;85:905-919.
15. Seymour RA, Smith DG, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodontol 1985;12:413-419.
16. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine induced gingival overgrowth. J Clin Periodontol 1993;20:37-40.
17. Kabra PM, Nelson MA, Marton LJ. Simultaneous very fast liquid-chromatographic analysis of ethosuximide, primidone, phenobarbital, phenytoin and carbamazepine in serum. Clin Chem 1983;29: 473-476.
18. Penarrocha-Diago M, Bagan-Sebastian JV, Vera-Sempere F. Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study. J Periodontol 1990;61:571-574.
19. Thomason JM, Seymour RA, Rawlins MD. Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice. Community Dent Oral Epidemiol 1992;20: 288-291.
20. Aas E. Hyperplasia gingivae diphenylhydantoinea. A clinical, histological, and biochemical study. Acta Odontol Scand 1963;21(Suppl. 34):1-142.
21. Reynolds F, Ziroyanis PN, Jones NF, Smith SE. Salivary phenytoin concentrations in epilepsy and in chronic renal failure. Lancet 1976;2:384-386.
22. Horning MG, Brown L, Nowlin J, Lertratanangleon K, Kelloway P, Zion TE. Use of saliva in therapeutic drug monitoring. Clin Chem 1977;23:157-164.
23. Paxton JW, Rowell FJ, Ratcliffe JD, et al. Salivary phenytoin radioimmunoassay. A simple method for the assessment of non-protein bound drug concentrations. Eur J Clin Pharmacol 1977;11:71-74.
24. Paxton JW, Whiting B, Stephen KW. Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. Br J Clin Pharmacol 1977;4:185-191.
25. Mucklow JC, Bending MR, Kahn GC, Dollery CT. Drug concentration in saliva. Clin Pharmacol Ther 1978;24:563-570.
26. Hoppel C, Carle M, Rane A, Sjoqvist F. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients. Clin Pharmacol Ther 1977;21:294-300.
27. Conard GJ, Haavik CO, Finger KF. Binding of 5,5-diphenylhydantoin and its major metabolite to human and rat plasma proteins. J Pharm Sci 1971;60:1642-1646.
28. Matzke GR, Brundage RC, Sawchuk RJ. Protein binding of phenytoin, p-hydroxy phenytoin, and p-hydroxy phenytoin glucuronide. J Clin Pharmacol 1986;26:677-679.
29. Steinberg A. Phenytoin penetration through sulcular tissues and its possible relationship to phenytoin-induced gingival overgrowth. In: Hassell TM, Johnson MC, Dudley KH, eds. Phenytoin-Induced Tetralogy and Gingival Pathology. New York: Raven Press, 1980;179-187.
30. McGaw TM, Lam S. Coates J. Cyclosporin-induced gingival overgrowth: correlation with dental scores and cyclosporin levels in serum and saliva. Oral Surg Oral Med Oral Pathol 1987;64:293-297.
31. Ayers GJ, Burnett D. Drug formulation and salivary phenytoin measurements. Lancet 1977;1:656.
32. Bochner F, Hooper WD, Sutherland JM, Eadie MJ, Tyner JH. Diphenylhydantoin concentrations in saliva. Arch Neurol 1974;31:57-59.
33. Cook CE, Ameson E, Poole WK, Lesser P, O'Tuama L. Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay. Clin Pharm Ther 1975;18:742-747.
34. Schmidt D, Kupferberg HJ. Diphenylhydantoin, phenobarbital and primidone in saliva, plasma and cerebrospinal fluid. Epilepsia 1975;16:735-741.
35. Hassell TM, O'Donnel J, Pearlman J, Tesini D, Best H, Murphy T. Salivary phenytoin levels in institutionalized epileptics. J Chron Dis 1983;36:899-906.
36. Kapur RN, Girgis S, Little TM, Masotti RE. Diphenylhydantoin-induced gingival hyperplasia: its relationship to dose and serum level. Dev Med Child Neurol 1973;15:483-487.
37. Little TM, Girgis SS, Masotti RE. Diphenylhydantoin-induced gingival hyperplasia: its response to changes in drug dosage. Dev Med Child Neurol 1975;17:421-424.
38. Ellis JS, Seymour RA, Monkman SC, Idle JR. Gingival sequestration of nifedipine in nifedipine-induced gingival overgrowth (letter). Lancet 1992;339:1382-1383.
39. Ellis JS, Seymour RA, Thomason JM, Monkman SC, Idle JR. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth (letter). Lancet 1993;341:1102-1103.
40. Hassell TM, Page RC, Narayanan AS, Cooper CG. Diphenylhydantoin (Dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. Proc Natl Acad Sci (USA) 1976;73:2909-2912.